Ipratropium Bromide Accord Healthcare

Ipratropium bromide, the active ingredient in Ipratropium Bromide Accord Healthcare, is an anticholinergic bronchodilator presented as an inhalation solution for inhalation use. It is used to relieve bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) and asthma. GNH USA supplies Ipratropium Bromide Accord Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipratropium bromide is a bronchodilator that acts on the muscarinic receptors of the airway smooth muscle, helping to manage obstructive airway diseases.

- Chronic obstructive pulmonary disease (COPD): improves airflow and reduces symptoms of breathlessness. - Asthma: provides additional bronchodilation as part of a maintenance regimen. - Exercise‑induced bronchospasm: can be used to prevent bronchoconstriction during physical activity.

Ipratropium bromide may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: reduced salivary secretion. - Cough: irritation of the airway. - Throat irritation: mild soreness after inhalation. - Hoarseness: temporary voice changes. - Headache: mild, transient. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Paradoxical bronchospasm: sudden worsening of breathing. - Allergic reaction: rash, itching, or angioedema. - Severe cough or chest tightness. - Respiratory distress: difficulty breathing. - Anaphylaxis: rare, life‑threatening hypersensitivity. - Acute urinary retention: especially in predisposed patients.

Before prescribing ipratropium bromide, clinicians should consider several safety aspects. - Assess respiratory status: evaluate severity of COPD or asthma before initiation. - Monitor for paradoxical bronchospasm: discontinue if symptoms worsen. - Avoid in patients with known hypersensitivity to ipratropium or atropine derivatives. - Use with caution in narrow‑angle glaucoma: anticholinergic effects may increase intra‑ocular pressure. - Use with caution in patients with urinary retention or prostatic hypertrophy. - Store below 25°C: keep in the original container, protect from moisture and light.

Ipratropium bromide can interact with other medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other anticholinergic agents: may increase anticholinergic side‑effects such as dry mouth and urinary retention. - Use with potent cholinergic antagonists: risk of additive bronchodilation leading to tachycardia.

Moderate Interactions (Monitor Closely): - Beta‑2 agonists (e.g., albuterol): monitor for additive bronchodilation and potential tachycardia. - Theophylline: may require serum level monitoring. - Antihistamines: increased anticholinergic load may enhance dry mouth. - Diuretics: watch for urinary retention in susceptible individuals.